Pathoquest Revenue and Competitors

PathoQuest, spin out of Institut Pasteur, is a genomic expert company offering a game-changing next-generation sequencing (NGS) platform for microbiology testing. The company has developed 2 applications: • The QC of biological drugs (ATMP, Vaccines, antibodies…) allowing robust and fast analysis under GLP grade. • The diagnosis of bloodstream Infections (including sepsis) directly from blood. PathoQuest's technology combines proprietary sample preparation protocols, applicable to several types of biological samples with proprietary pathogen genome sequence databases and automated analysis pipelines. BIOLOGICS TESTING OFFER PathoQuest offers Biotech and biopharmaceutical companies GLP grade solutions to secure the biosafety of biological drugs like cell & gene therapy products, vaccines and, recombinants by preventing adventitious agent contamination and cell-line misidentification. Advanced NGS-based solutions supplement or replace traditional testing methods and support the strategic decision-making process allowing for a robust and unambiguous level of testing and faster turnaround time. Based in Paris, France, PathoQuest has established a U.S. subsidiary and is expanding its capabilities by implementing a state-of-the-art testing facility at its location near Philadelphia. The company has also signed in 2018 a strategic partnership with Charles River Lab (Boston, USA) DIAGNOSIS OF BLOODSTREAM INFECTIONS - PathoQuest has developed iDTECT® Blood Test, the first and only clinical CE In Vitro Diagnostic (IVD) metagenomic test for infectious diseases. - The test provides directly from blood to clinicians and microbiologists an improved method for detecting pathogens, particularly for immunocompromised patients with suspected infections. This new molecular diagnostic test is designed to improve antibiotic stewardship and lead to better patient care through personalized treatment. For more information about PathoQuest, feel free to reach out!